The number of shareholders in the period ended October 22 was 32.78% lower than that in the period ended October 22. This is the second consecutive decline in the number of shareholders of the company.
According to the statistics of securities times · data treasure, as of press time, Beijing Sun-Novo Pharmaceutical Research Co.Ltd(688621) closing price was 99.82 yuan, down 2.55%. Since the concentration of chips in this period, the stock price has fallen by 3.55%. Specific to each trading day, it rose three times and fell five times.
According to the data of margin trading and securities lending, the latest (March 21) two financing balance of the stock was 914947 million yuan, of which the financing balance was 823972 million yuan. Since the concentration of chips in this period, the total financing balance has increased by 1.8407 million yuan, an increase of 2.29%.
According to the data released by the company in 2021, in 2021, the company achieved a total operating revenue of 494 million yuan, a year-on-year increase of 42.12%, a net profit of 106 million yuan, a year-on-year increase of 45.81%, a basic earnings per share of 1.5100 yuan and a weighted average return on net assets of 22.22%.
From the perspective of agency rating, the stock has been bought by two agency ratings in the past month. It is estimated that the highest target price is Orient Securities Company Limited(600958) . The research report issued by Orient Securities Company Limited(600958) on March 2 gives the company a target price of 104.40 yuan.
